瑞康医药股票讨论区

The market may believe the company's recent revenue performance is insufficient compared to the industry, given its low P/S ratio. Without top-line growth improvement, the ratio could fall further. Given recent revenue trends, significant share price movement seems unlikely soon.

The company's consistent loss and lack of revenue growth over the past five years make it an unattractive investment. However, contrarian investors might want to research the stock in hope of a turnaround.